Brain Tumour

Scientists have used a new device to identify a key membrane protein in urine that indicates whether the patient has a brain tumour. According to their study, the protein used to detect brain cancer could avoid the need for invasive tests, and increase the likelihood of tumours being detected early enough for surgery. This research from Nagoya University, Japan, could also have potential implications for detecting other types of cancer, the study said. The research was published in the journal ACS Nano. Although early detection of many types of cancer has contributed to the recent increases in cancer survival rates, the survival rate for brain tumours has remained almost unchanged for over 20 years. This is partly due to their late detection. Physicians often discover brain tumours only after the onset of neurological symptoms, such as loss of movement or speech, by which time the tumour has reached a considerable size. Detecting the tumour when it is still small, and starting ..

AI can be trained to detect whether or not a tissue picture contains a tumour. However, until recently, it has remained a mystery as to how it makes its judgement

Combining research with cutting-edge technology, a Delhi-based hospital on Sunday launched a "brain mapping device" and claimed it was the first-of-its-kind gadget in the country. With the advent of such personalised brain mapping, treatment for brain tumour and other brain surgeries have become much safer and due to the accuracy, damage to important brain areas can be avoided, it said in a statement. "In a first-of-its-kind technology to be launched, with combination of decades of research with cutting edge technology, IBS Hospitals today launched first brain mapping device connectomics/ quicktome in the country," the private hospital claimed. Quicktome uses sophisticated algorithms to analyse millions of data points and build a brain map personalised to each patient from a standard, non-invasive MRI scan. The maps, which doctors can view on their computers, offer a level of anatomical detail typically not available in a clinical setting, allowing surgeons to incorporate advance

The HTL-001 peptide used in the study has undergone safety testing and is suitable for patient trials. These trials are now being considered in GBM and other cancers

According to the study, cancer cells generally vary in the number of copies of each gene or chromosome present in their genome -- a phenomenon known as copy number alterations or CNAs

If the blood supply to brain gets affected, it may over long term, lead to paralysis, stroke or even death